Journal: Science Progress

Article Title: A Serum DLL1 and CRP dual-marker model for bacterial infection detection in patients with decompensated cirrhosis: A dual-cohort diagnostic study

doi: 10.1177/00368504251358310

Figure Lengend Snippet: Differential expression of DLL1 according to infection status and infection site in decompensated cirrhosis patients (derivation cohort). (a) Comparison of serum DLL1 levels between patients with BIs and noninfected controls in the derivation cohort. Compared with non-BI controls, patients with BI presented significantly elevated DLL1 levels (P < 0.001, Mann–Whitney U test). (b) Analysis of DLL1 expression stratified by infection type, including SBP, pneumonia, and others. No statistically significant differences were observed across infection types (Kruskal–Wallis test, P = 0.214). BI: bacterial infection; DLL1: Delta-like ligand 1; SBP: spontaneous bacterial peritonitis.

Article Snippet: Serum DLL1 levels were quantified using a commercial enzyme-linked immunosorbent assay kit (Boster Biotech EK1276, Wuhan, China; detection range: 78–5000 pg/mL; sensitivity: < 2 pg/mL) following a standardized protocol: 50 μL of serum was diluted 1:2 with assay buffer, incubated with anti-DLL1 antibodies for 1 hour at 37°C, and measured at 450 nm.

Techniques: Quantitative Proteomics, Infection, Comparison, MANN-WHITNEY, Expressing

Journal: Science Progress

Article Title: A Serum DLL1 and CRP dual-marker model for bacterial infection detection in patients with decompensated cirrhosis: A dual-cohort diagnostic study

doi: 10.1177/00368504251358310

Figure Lengend Snippet: Diagnostic performance of serum biomarkers for BI (derivation cohort). (a) ROC curves for the CRP, DLL1, and combined models for the diagnosis of BI in patients with decompensated cirrhosis. DeLong's test revealed the following: CRP versus DLL1 (P = 0.062), CRP versus the combined model (P < 0.00), and DLL1 versus the combined model (P = 0.002). (b) DCA revealed that the combined model provided a net benefit superior to that of the CRP or DLL1 models alone across threshold probabilities of 10%-80%. (c) Calibration curve: the observed versus predicted probabilities aligned closely with the ideal line (Hosmer–Lemeshow, P = 0.73), indicating good model fit. The integrated analysis highlights the additive diagnostic value of combining CRP and DLL1 levels, with improved discrimination (AUC), clinical utility (DCA), and calibration accuracy. AUC: area under the curve; CRP: C-reactive protein; DCA: decision curve analysis; DLL1: delta-like ligand 1; ROC: receiver operating characteristic.

Article Snippet: Serum DLL1 levels were quantified using a commercial enzyme-linked immunosorbent assay kit (Boster Biotech EK1276, Wuhan, China; detection range: 78–5000 pg/mL; sensitivity: < 2 pg/mL) following a standardized protocol: 50 μL of serum was diluted 1:2 with assay buffer, incubated with anti-DLL1 antibodies for 1 hour at 37°C, and measured at 450 nm.

Techniques: Diagnostic Assay, Biomarker Discovery

Journal: Science Progress

Article Title: A Serum DLL1 and CRP dual-marker model for bacterial infection detection in patients with decompensated cirrhosis: A dual-cohort diagnostic study

doi: 10.1177/00368504251358310

Figure Lengend Snippet: Diagnostic performance of the CRP, PCT, DLL1, and combined models in the subgroup with PCT data. PCT data were available for 143 patients in the derivation cohort and 59 patients in the validation cohort. (a) CRP (AUC = 0.796), PCT (AUC = 0.819) and DLL1 (AUC = 0.901) showed comparable diagnostic efficacy. (b) The CRP–DLL1 dual-marker model demonstrates superior diagnostic accuracy compared to CRP–PCT combination and individual biomarkers (CRP, DLL1, PCT) in the PCT-included subgroup (all DeLong's P < 0.05). AUC: area under the curve; CRP: C-reactive protein; DLL1: delta-like ligand 1; PCT: procalcitonin.

Article Snippet: Serum DLL1 levels were quantified using a commercial enzyme-linked immunosorbent assay kit (Boster Biotech EK1276, Wuhan, China; detection range: 78–5000 pg/mL; sensitivity: < 2 pg/mL) following a standardized protocol: 50 μL of serum was diluted 1:2 with assay buffer, incubated with anti-DLL1 antibodies for 1 hour at 37°C, and measured at 450 nm.

Techniques: Diagnostic Assay, Biomarker Discovery, Marker

Journal: Science Progress

Article Title: A Serum DLL1 and CRP dual-marker model for bacterial infection detection in patients with decompensated cirrhosis: A dual-cohort diagnostic study

doi: 10.1177/00368504251358310

Figure Lengend Snippet: Correlations between DLL1 levels and the levels of key clinical parameters (derivation and validation cohorts). (a) Spearman's correlation coefficient: total bilirubin level (R = 0.229, P < 0.001); (b) serum creatinine level (ρ=0.314, P = 0.002); and (c) CRP level (ρ=0.335, P < 0.001). CRP: C-reactive protein; DLL1: Delta-like ligand 1.

Article Snippet: Serum DLL1 levels were quantified using a commercial enzyme-linked immunosorbent assay kit (Boster Biotech EK1276, Wuhan, China; detection range: 78–5000 pg/mL; sensitivity: < 2 pg/mL) following a standardized protocol: 50 μL of serum was diluted 1:2 with assay buffer, incubated with anti-DLL1 antibodies for 1 hour at 37°C, and measured at 450 nm.

Techniques: Biomarker Discovery